

## **National Cooperative Reprogrammed Cell Research Groups (NCRCRG) and Convergent Neuroscience (CN) 2020 Consortium Registration Form**

*Public reporting burden for this collection of information is estimated to average 1 minute per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number (OMB# 0925-0740; Exp date 7/31/2022). Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.*

This event is hosted by the National Institute of Mental Health

### About this Event

Thanks for participating in the upcoming NIMH workshop & consortium meeting. Please register at this site so that we can prepare participant lists and related meeting documentation. Please also read the information below to help you prepare for the meeting.

### About the Meeting

This NIMH grantees meeting will be an opportunity to discuss areas of emerging progress, opportunity or need. In particular, NIMH has identified work being done in several areas where investigator interaction and the exchange of new findings may accelerate the pace of progress in functional genomics and developing cell-based assays for identifying disease mechanism, novel therapeutic targets and/or drug discovery. To facilitate this, there will be a balance of concise research progress slide presentations, a virtual poster session on day 1, along with issue-oriented discussion and brainstorming on both days.

**NCRCRG:** Per PAR-13-225, these academic-industry partnerships use patient-derived reprogrammed cells to develop validated platforms for identifying novel targets and developing new therapeutics or diagnostic tools to reduce the burden of mental illness. The collaborations will be pre-competitive, meaning that they lie at the interface between basic academic research and proprietary industrial research and involve cooperation between groups that might otherwise be competitors, with a focus on optimizing tools and measures needed for successful translational research. The teams will further develop promising cellular differentiation/characterization protocols and/or disease-relevant assays using patient-derived reprogrammed cells (e.g., induced pluripotent stem cells or iPSCs, induced neuronal cells or iNCs). Critical features of these efforts are (1) a strong emphasis on developing methodology that is robust and replicable across several performance sites, and (2) cross-paradigm validation to yield predictive value for pathophysiology.

**Convergent Neuroscience (CN):** Per PAR-17-179, teams use multidisciplinary approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, behavior) in an explanatory model of psychopathology. In particular, teams focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena. The projects bring together inter/transdisciplinary teams from neuroscience and "orthogonal" fields (e.g., data/computational science, physics, engineering, mathematics, and environmental sciences). Teams will develop data-driven theoretical approaches and computational models that connect

contiguous levels of analysis, which will be tested experimentally to elucidate biological underpinnings of complex systems level outcomes in psychopathology.

In the spirit of strategic alliances to meet the objectives of the program, there can be ad hoc participation of PD/PIs from one or more relevant research projects, centers, networks or consortia, e.g., with NIH R01, P50, U01, U19, U54, U24 awardees, as well as other qualified scientists, to gain the advantages of broader consideration of research methods for validation, qualification, or creation of public research resources for translational research.

A complete agenda is being finalized and will be distributed shortly.

Please visit <https://zoom.us/download> to upgrade to the latest version of Zoom.

LINK TO JOIN Be on the lookout for an email with a link to join the meeting and a separate link to join the poster session, closer to the meeting date. POSTER SESSION: This will be hosted by a separate Zoom link on Thursday afternoon (Nov 19). In order to self-select breakout rooms, users must be running Zoom 5.3.0 or later. Please visit <https://zoom.us/download> to upgrade to the latest version of Zoom.

---

## Contact Information

First name\*(required)

Last name\*(required)

Email\*(required)

Confirm email\*(required)

## Ticket 1 · Attendee

First name\*(required)

Last name\*(required)

Suffix

Email\*(required)

Job title

Company\*(required)

**Please select which days you plan on attending (check all that apply). \*(required)**

DAY 1: Thursday, October 19th (11:00 am - 5:00 pm)

POSTER SESSION: Thursday, October 19 (3:00 pm - 5:00 pm)



DAY 2: Friday, October 20th (11:00 am - 5:00 pm)

**Please let us know if you would like to present a poster. \*(required)**

Yes

No

---